Autolus Therapeutics

NASDAQ: AUTL · Real-Time Price · USD
1.73
-0.12 (-6.49%)
At close: Aug 15, 2025, 3:59 PM
1.76
1.73%
After-hours: Aug 15, 2025, 07:55 PM EDT

Autolus Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
10.12M 1.7M 6.19M 2.33M
Cost of Revenue
11.39M 6.57M 137.22M 128.65M
Gross Profit
-1.27M -4.87M -131.03M -126.32M
Operating Income
-241.43M -195.03M -163.78M -164.21M
Interest Income
32.35M 13.51M 1.71M 262K
Pretax Income
-219.13M -208.4M -173.21M -165.99M
Net Income
-220.66M -208.38M -148.84M -142.1M
Selling & General & Admin
101.09M 46.74M 31.9M 31.86M
Research & Development
138.44M 149.98M 141.99M 134.79M
Other Expenses
637K n/a -166K -145K
Operating Expenses
239.52M 1.7M 173.72M 166.65M
Interest Expense
9.29M 45.07M 8.9M 1.1M
Selling & Marketing Expenses
n/a 1.1M n/a n/a
Cost & Expenses
250.91M 196.73M 173.72M 166.65M
Income Tax Expense
1.53M -19K -24.37M -23.89M
Shares Outstanding (Basic)
255.16M 173.94M 94.99M 72.08M
Shares Outstanding (Diluted)
255.16M 173.94M 94.99M 72.08M
EPS (Basic)
-0.86 -1.2 -1.57 -1.97
EPS (Diluted)
-0.86 -1.2 -1.57 -1.97
EBITDA
-182.42M -156.77M -135.54M -132.01M
EBIT
-209.84M -163.34M -139.66M -140.93M
Depreciation & Amortization
7.72M 6.57M 7.42M 8.55M